小分子，大世界。40亿美金首付的TYK2。
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
- Nimbus to receive $4 billion in upfront cash, and up to $2 billion in commercial milestone payments -
- NDI-034858 has potential best-in-class profile among new therapeutic class of selective allosteric TYK2 inhibitors for immune-mediated diseases -